CN Bio
CN Bio Innovations is a leading organ-on-a-chip company that designs and manufactures microphysiological systems (MPS) to generate human-specific efficacy and safety data. Their PhysioMimix® platform models human biology to improve drug discovery, reduce animal testing, and support the development of new therapeutics. They collaborate with regulatory agencies like the FDA and partner with pharmaceutical and biotech companies worldwide. Their solutions include assays for drug-induced liver injury (DILI), ADME, drug absorption, and more, providing advanced, human-relevant models for preclinical testing.
Industries
Nr. of Employees
medium (51-250)
CN Bio
332 Cambridge Science Park, Milton Road, Cambridge, CB4 0WN, UK
Products
Benchtop organ-on-chip controller and instrumentation
Laboratory-scale controller and instrumentation that operate open-well multi-chip plates and control recirculating microfluidics to create single- or multi-organ perfused 3D microtissues.
Multi-chip plates and scaffold consumables
Engineered multi-chip plate formats and scaffold consumables designed for 3D perfused microtissue formation, tissue recovery and longitudinal sampling.
Validated primary 3D human cell lots
Catalog of primary human cells validated for performance in perfused 3D microtissue assays to support reproducibility across disease and toxicity models.
Disease-model reagent kit for metabolic liver disease
Consumable kit and protocol package to recreate a validated tri-culture liver disease assay in the laboratory, including validated cells, media and SOPs for multi-week experiments.
DILI assay kit (human-24 format)
Assay kit containing validated reagents and protocols to recreate an in vitro hepatotoxicity assay with clinical biomarker readouts in a laboratory setting.
Bioavailability assay kit (human-18 format)
Consumable kit enabling in vitro profiling of human oral drug bioavailability using perfused multi-organ assays.
Benchtop organ-on-chip controller and instrumentation
Laboratory-scale controller and instrumentation that operate open-well multi-chip plates and control recirculating microfluidics to create single- or multi-organ perfused 3D microtissues.
Multi-chip plates and scaffold consumables
Engineered multi-chip plate formats and scaffold consumables designed for 3D perfused microtissue formation, tissue recovery and longitudinal sampling.
Validated primary 3D human cell lots
Catalog of primary human cells validated for performance in perfused 3D microtissue assays to support reproducibility across disease and toxicity models.
Disease-model reagent kit for metabolic liver disease
Consumable kit and protocol package to recreate a validated tri-culture liver disease assay in the laboratory, including validated cells, media and SOPs for multi-week experiments.
DILI assay kit (human-24 format)
Assay kit containing validated reagents and protocols to recreate an in vitro hepatotoxicity assay with clinical biomarker readouts in a laboratory setting.
Bioavailability assay kit (human-18 format)
Consumable kit enabling in vitro profiling of human oral drug bioavailability using perfused multi-organ assays.
Services
Design and execution of bespoke or standard in vitro studies using perfused microphysiological systems to generate safety, efficacy and ADME data for drug development programs.
Execution of human liver microtissue hepatotoxicity studies with clinical biomarker reporting, dose–response analysis and optional inclusion of immune components for immune-mediated toxicity investigation.
Tri-culture liver disease assays to model steatosis, inflammation and fibrosis for evaluation of therapeutic efficacy and mechanism, provided as standard or bespoke CRO projects.
Assays to evaluate drug absorption, metabolism, bioavailability and targeted oligonucleotide uptake/knockdown using perfused microtissues with imaging, molecular and LC‑MS endpoints.
Design and execution of bespoke or standard in vitro studies using perfused microphysiological systems to generate safety, efficacy and ADME data for drug development programs.
Execution of human liver microtissue hepatotoxicity studies with clinical biomarker reporting, dose–response analysis and optional inclusion of immune components for immune-mediated toxicity investigation.
Tri-culture liver disease assays to model steatosis, inflammation and fibrosis for evaluation of therapeutic efficacy and mechanism, provided as standard or bespoke CRO projects.
Assays to evaluate drug absorption, metabolism, bioavailability and targeted oligonucleotide uptake/knockdown using perfused microtissues with imaging, molecular and LC‑MS endpoints.
Expertise Areas
- Microphysiological systems (organ-on-chip) development
- In vitro safety toxicology and drug-induced liver injury assessment
- ADME/DMPK profiling and oral bioavailability testing
- Disease modelling for metabolic liver disorders and fibrosis
Key Technologies
- Organ-on-chip microphysiological platforms
- Perfused 3D tissue culture on engineered scaffolds
- Recirculating microfluidic flow control and automation
- Open-well multi-chip plate formats (12- and 48-well equivalents)
News & Updates
CN Bio announced the appointment of Dr Paul Brooks as Chief Business Officer to lead its global commercial strategy.
The company launched a new assay kit for predicting drug-induced liver injury.
Partnership to provide local support and expand access in Japan.
CN Bio announced the appointment of Dr Paul Brooks as Chief Business Officer to lead its global commercial strategy.
The company launched a new assay kit for predicting drug-induced liver injury.
Partnership to provide local support and expand access in Japan.